Although the brain is known to contain specific insulin receptors, there is no information on whether these receptors are also present in the peripheral nervous system (PNS). The present studies sought to provide this information by characterizing insulin binding in bovine autonomic (superior cervical) and sensory (trigeminal) ganglia. It was found that both ganglia contain specific, high-affinity receptors for insulin. Like insulin receptors in other tissue, these receptors could be solubilized and purified on wheat germ agarose columns and were found to have tyrosine-specific kinase activity. SDS-PAGE and autoradiography revealed that the apparent molecular weight (Mr) of the PNS insulin receptor was approximately 133 kDa which is similar to the Mr of hepatic receptors, but is approximately 10 kDa larger than the insulin receptor found in the brain. Because the vasculature of autonomic and sensory ganglia is fenestrated, it is possible that PNS insulin receptors are exposed to blood-borne insulin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0006-8993(87)90704-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Xylooligosaccharide and Akkermansia muciniphila synergistically ameliorate insulin resistance by reshaping gut microbiota, improving intestinal barrier and regulating NKG2D/NKG2DL signaling in gestational diabetes mellitus mice.
Food Res Int
February 2025
Department of Nutrition and Food Hygiene, NMPA Key Laboratory for Safety Evaluation of Cosmetics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, 1026. Shatai South Road, Guangzhou 510515, Guangdong, PR China; Department of Clinical Nutrition, Nanfang Hospital, Southern Medical University, 1838. Guangzhou Avenue North, Guangzhou 510515, Guangdong, PR China. Electronic address:
Xylooligosaccharides (XOS) ameliorate insulin resistance (IR) in gestational diabetes mellitus (GDM) probably by propagating Akkermansia muciniphila (Akk). This study aimed to investigate the effects and mechanisms of XOS, Akk and combination on IR in GDM mice/pseudo-germ-free (PGF) mice. Female mice were fed with AIN-93 (n = 19) and high fat diet (HFD) (n = 206).
View Article and Find Full Text PDFJAK inhibitors: a new choice for diabetes mellitus?
Diabetol Metab Syndr
January 2025
Department of Cardiology, Zibo Central Hospital, No. 10, South Shanghai Road, Zibo, People's Republic of China.
Altered tyrosine kinase signaling is associated with a variety of diseases. Tyrosine kinases can be classified into two groups: receptor type and nonreceptor type. Nonreceptor-type tyrosine kinases are subdivided into Janus kinases (JAKs), focal adhesion kinases (FAKs) and tec protein tyrosine kinases (TECs).
View Article and Find Full Text PDFThe expression of chromosome 19 miRNA cluster members during insulin sensitivity changes in pregnancy.
Placenta
January 2025
Mother Infant Research Institute, Tufts Medicine, Boston, MA, USA; Dept Obstetrics & Gynecology, Tufts University, Boston, MA, USA. Electronic address:
Hypothesis: Declines in insulin sensitivity during pregnancy important for fetal growth are associated with impairments in skeletal muscle post-receptor insulin signaling. The primary initiator of these changes is unknown but believed to originate in the placenta. We hypothesize that placental miRNAs are associated with maternal sensitivity changes and impact insulin-sensitive mechanisms in target tissues in vitro.
View Article and Find Full Text PDFEngineering of a lysosomal-targeted GAA enzyme.
Protein Eng Des Sel
January 2025
Pfizer Rare Disease Research Unit, 610 Main Street, Cambridge, MA 02139, United States.
Pompe disease is a tissue glycogen disorder caused by genetic insufficiency of the GAA enzyme. GAA enzyme replacement therapies for Pompe disease have been limited by poor lysosomal trafficking of the recombinant GAA molecule through the native mannose-6-phosphate-mediated pathway. Here, we describe the successful rational engineering of a chimeric GAA enzyme that utilizes the binding affinity of a modified IGF-II moiety to its native receptor to bypass the mannose-6-phosphate-mediated lysosomal trafficking pathway, conferring a significant increase in cellular uptake of the GAA enzyme.
View Article and Find Full Text PDFEarly Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.
Infect Dis Rep
January 2025
Royal Brompton Hospital, Part of GSTT NHS Foundation Trust, London SW3 6NP, UK.
Background: Glucagon-like peptide-1 (GLP-1) agonists are an existing treatment option for patients with insulin-resistant states, which elicit further pleiotropic effects related to immune cell recruitment and vascular inflammation. GLP-1 agonists downregulate the cluster of differentiation 147 (CD147) receptor, one of several receptors for the SARS-CoV-2 spike protein that mediate viral infection of host cells.
Methods: We conducted an open-label prospective safety and tolerability study including biomarker responses of the GLP-1 agonist Liraglutide, administered for 5 days as an add-on therapy to the standard of care within 48 h of presentation in a cohort of 13 patients hospitalized with COVID-19 pneumonia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!